



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

9

Application Number

09/942,310

Filing Date

08/29/2001

First Named Inventor

RISINGER

Art Unit

1634

Examiner Name

GOLDBERG, JEANINE ANNE

Attorney Docket Number

SGL-2019-UT

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-2038 in the amount of \$180.00
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Remarks</b> Cover letter - 2 pages SB08 - 1 page Return postcard - 1 page Transmittal form (in duplicate) - 2 pages Fee Transmittal (in duplicate) - 2 pages PTO-2038 - 1 page 18 documents	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Biotechnology Law Group		
Signature			
Printed name	Bruce D. Grant		
Date	April 14, 2006	Reg. No.	47,608

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Reginald J. Gaudino	Date	4/19/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2006

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

### Complete if Known

Application Number	09/942,310
Filing Date	August 29, 2001
First Named Inventor	RISINGER
Examiner Name	GOLDBERG, JEANINE ANNE
Art Unit	1634
Attorney Docket No.	SGL-2019-UT

### METHOD OF PAYMENT (check all that apply)

☐ Check ☒ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_

☐ Deposit Account Deposit Account Number: \_\_\_\_\_ Deposit Account Name: \_\_\_\_\_

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee  
☐ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☐ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

### FEE CALCULATION

#### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

#### 2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180
<b>Total Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>
0 - 20 or HP = 0 x 0 = 0		
HP = highest number of total claims paid for, if greater than 20.		
<b>Indep. Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>
0 - 3 or HP = 0 x 0 = 0		
HP = highest number of independent claims paid for, if greater than 3.		

#### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets - 100 = 0 / 50 = 0 (round up to a whole number) x 0 = 0

#### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement

Fees Paid (\$)

\$180.00

#### SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	47,608	Telephone	(858) 623-9470
Name (Print/Type)	Bruce Grant	Date	April 14, 2006		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RISINGER et al  
Serial No.: 09/942,310  
Filed: August 29, 2001  
Title: Detection of CYP2D6 Polymorphisms

Examiner: Goldberg, Jeanine A  
Group Art Unit: 1634  
Docket: SGL-2019-UT

---

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Applicants also bring to the Examiner's attention the existence of two co-pending related applications, 09/943,531 (Attorney Docket: SGL-2020-UT), filed August 30, 2001 (Examiner Sakelaris, Sally A) and published March 27, 2003 as US20030059774 A1 and 09/943,115 (Attorney Docket: SGL-2021-UT), filed August 30, 2001 (Examiner Johannsen, Diana B).

**INFORMATION DISCLOSURE STATEMENT**

Serial No.: 09/942,310

Filing Date: August 29, 2001

Title: Detection of CYP2D6 Polymorphisms

Page 2  
Dkt: SGL-2019-UT

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), after the mailing date of the first office action on the merits, but prior to the final office action.

Accordingly, Applicants respectfully submit payment of \$180.00.


If Applicant has submitted the wrong fee for filing of the Information Disclosure Statement, please contact the undersigned attorney at (858) 623-9470.


The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Date April 14, 2004  
BioTechnology Law Group  
527 N. Highway 101, Suite E  
Solana Beach, CA 92075-1173  
Telephone: (858) 623-9470  
Fax: (858) 623-9476  
Email: [bruce@biotechnologylawgroup.com](mailto:bruce@biotechnologylawgroup.com)

Respectfully submitted,

By

  
Bruce Grant  
Reg. No. 47,608



Substitute form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

<b>Complete if Known</b>	
<b>Application Number</b>	09/942,310
<b>Filing Date</b>	08/29/2001
<b>First Named Inventor</b>	RISINGER
<b>Group Art Unit</b>	1634
<b>Examiner Name</b>	GOLDBERG, JEANINE ANNE
<b>Attorney Docket No: SGL-2019-UT</b>	

Sheet 1 of 1

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	5,912,120	06/15/1999	Goldstein et al	
	A2.	5,786,191	07/28/1998	Goldstein et al	
	A3.				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A4.	WO 00/12757	03/09/2000	Hauzenberger		
	A5.	WO-95/30766	11/16/1995	Goldstein et al		
	A6.	GB 2371091	07/17/2002	Williams et al		
	A7.					

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A8.	Gaedigk et al., Clinical Chemistry, 49(6):1008-1011 (2003)	
	A9.	RAIMUNDO et al., Clinical Pharmacology and Therapeutics, 76(2):128-138 (2004)	
	A10.	Soyama et al, Drug Metab. Pharmacokin., 19(4):snp19(313)-snp25(319) 2004	
	A11.	Yamazaki et al., Drug Metab. Pharmacokin., 18(4):snp26(269)-snp28(271) 2003	
	A12.	Lovlie et al., Pharmacogenetics, 11(1):45-55 (2001)	
	A13.	Karam et al., Drug Metabolism and Disposition, 24(10):1081-1087 (1996)	
	A14.	EMBL Database accession no. AR071577	
	A15.	Kim et al., Clinical Pharmacology and Therapeutics, MOSBY year book 69(2):39 (2001)	
	A16.	Excoffier and Slatkin, Mol. Biol. Evol., 12(5):921-927 (1995)	
	A17.	Cytochrome P450 (CYP) Allele Nomenclature Committee. <a href="http://www.imm.ki.se/cypalleles">http://www.imm.ki.se/cypalleles</a>	
	A18.	Johannson et al., Molecular Pharmacology, 46:452-459 (1994)	
	A19.	Daly et al., Pharmacogenetics, 6(3):193-201 (1996)	
	A20.	Zanger et al., Pharmacogenetics 11(7):573-585 (2001)	
	A21.		

**EXAMINER**

**DATE CONSIDERED**